A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared with Levetiracetam as Monotherapy in Pediatric Subjects with New or Recent-Onset Epilepsy
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Topiramate (Primary) ; Levetiracetam
- Indications Epilepsy; Partial epilepsies; Tonic-clonic epilepsy
- Focus Adverse reactions; Registrational
- Sponsors Janssen Research & Development; Janssen-Cilag
- 14 Nov 2019 This trial has been completed in Austria, according to European Clinical Trials Database record.
- 10 Nov 2019 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 31 Oct 2019 Planned End Date changed from 31 May 2021 to 30 Nov 2021.